Emerging technologies, automated systems provide promising solutions for rapid bacterial ID and AST profiling

NewsGuard 100/100 Score

An SLAS Technology review article by Yiyan Li, Xing Yang and Weian Zhao of University of California, Irvine highlights and synthesizes representative emerging micro- and nanotechnologies, as well as automated systems for bacterial identification (ID) and antibiotic susceptibility testing (AST), including both phenotypic and molecular methods and those at the point-of-care (POC) setting. Also discussed are major remaining challenges and potential future endeavors toward improving clinical outcomes with rapid bacterial ID/AST technologies.

Rapid bacterial identification ID/AST are in great demand due to the rise of drug-resistant bacteria. Each year, two million people are sickened in the United States with infections resistant to antibiotics. At least 23,000 people die. The development and use of rapid testing technologies for resistant bacteria, that would enable physicians to make the right treatment decision within the critical treatment time span, has been identified as a priority to combat antibiotic resistance. Unfortunately, conventional culture-based methods suffer from a long turnaround time.

In recent years, major advances in miniaturization and automation provide promising solutions for rapid bacterial ID/AST profiling, which will potentially make a significant impact in the clinical management of infectious diseases and antibiotic stewardship.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Oral azithromycin reduces maternal sepsis and healthcare costs in low-resource settings